UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 11, 2005
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-32501 |
|
33-0827593 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 458-0900
(Registrant’s telephone number, including area code)
MacroPore Biosurgery, Inc.
6740 Top Gun Street,
San Diego, California 92121
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On July 11, 2005 MacroPore Biosurgery, Inc. changed its name to Cytori Therapeutics, Inc. The change was made to better reflect the company’s focus and significant progress in the development of regenerative therapeutics. The Company will continue to trade its shares on the Frankfurt Stock Exchange under the symbol XMP.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CYTORI THERAPEUTICS, INC. |
|||
|
|
|
|
||
|
|
|
|
||
|
Date: July 13, 2005 |
By: |
/s/ |
CHRISTOPHER J. CALHOUN |
|
|
|
|
Christopher J. Calhoun |
||
|
|
|
Chief Executive Officer |
||
3